Entries by admin

Kindred Biosciences Submits New Animal Drug Application Technical Section for Effectiveness for Mirataz to FDA

San Francisco, CA (August 22, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the submission of the Effectiveness Technical Section of the New Animal Drug Application for Mirataz™ (mirtazapine transdermal ointment) to the Food and Drug Administration (FDA) for the management of weight […]

Kindred Biosciences Announces Second Quarter 2016 Financial Results

San Francisco, CA (August 8, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the second quarter ended June 30, 2016 and provided updates on its programs. “We are on track to launch our two lead product candidates by the first […]

Kindred Biosciences Announces Initiation of Pilot Field Study of Atopic Dermatitis and Other Updates

San Francisco, CA (June 14, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, announced the initiation of a pilot field study designed to test several molecules, including anti-cytokine antibodies, in dogs with atopic dermatitis. The pilot field study in dogs with atopic dermatitis is a […]

Kindred Biosciences Announces HITS Sponsorship

San Francisco, CA (May 25, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, is pleased to announce their Platinum Sponsorship of the HITS Horse Show series.  The sponsorship will start this week at the Saugerties, New York facility for the HITS-on-the-Hudson series and will extend […]

Kindred Biosciences Announces Positive Results from Pivotal Study of KIND-010 for the Management of Weight Loss in Cats

Conference call and webcast scheduled for 4:30 p.m. ET / 1:30 p.m. PT today San Francisco, CA (May 16, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive topline results from its pivotal field study of KIND-010, mirtazapine transdermal gel, for the management […]